Grifols Achieves Positive Topline Results From Phase 4 : com

Clinical trial met primary endpoint demonstrating comparable total immunoglobulin (Ig) levels when administering XEMBIFY® (Grifols’ subcutaneous Ig) every...

Related Keywords

Canada , Spain , United States , Australia , China , Barcelona , Comunidad Autonoma De Cataluna , America , Spanish , Kim Hanna , Marketing Research Bureau , Spanish Stock Exchange , Clinical Development , Drug Administration , Investors Relations Department Sustainability , Media Press Office , United States Food , Grifols Senior Director Clinical , Immune Globulin , Chromatography Purified , Prescribing Information , North America , Middle East , Mercado Continuo , Royal Legislative Decree , Securities Market Law , Royal Decree Law , Royal Decree , Global Usage , Immunoglobulin Market , Nasdaq Grfs , Grifols , A ,